Lynparza Poised For Growth With Broad Ovarian Cancer Approval
Executive Summary
AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing, posing a threat to Tesaro's reigning Zejula.